Hydroxychloroquine Modulates the Progression of Experimentally Induced Benign Prostatic Hyperplasia in Rats via Targeting EGFR/ERK/STAT3 and AR/FOXO1/TRAIL Pathways: Computational and In Vivo Studies

    June 2025 in “ Scientific Reports ”
    Walaa H. El-Maadawy, Ehab Hafiz, Samer A. Tadros, Sally A. Fahim, Haidy M. Ebrahim, Marwa A. Fouad, Yasmin M. Attia
    TLDR Hydroxychloroquine may help treat benign prostatic hyperplasia by reducing inflammation and promoting cell death.
    This study investigates the therapeutic potential of hydroxychloroquine (HCQ) in treating benign prostatic hyperplasia (BPH) in rats, highlighting its ability to reduce prostate weight, PSA levels, and pro-inflammatory cytokines, while improving tissue histology. HCQ modulates BPH progression by targeting the EGFR/ERK/STAT3 and AR/FOXO1/TRAIL pathways, promoting apoptosis and reducing inflammation. The combination of HCQ with finasteride (Fin) enhances these effects. Molecular docking shows HCQ's strong interactions with key proteins involved in BPH, suggesting it as a promising treatment strategy either alone or with Fin.
    Discuss this study in the Community →

    Research cited in this study

    3 / 3 results